Telaprevir: Pharmacokinetics and drug interactions

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1211-1221

  Garg, Varun ^a   Kauffman, Robert S ^a   Beaumont, Maria ^b   Van Heeswijk, Rolf P G ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; BUPRENORPHINE; CYCLOSPORIN A; CYTOCHROME P450 3A; DIGOXIN; ESCITALOPRAM; ESOMEPRAZOLE; ETHINYLESTRADIOL PLUS NORETHISTERONE; KETOCONAZOLE; METHADONE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; TACROLIMUS; TELAPREVIR; ZOLPIDEM;

ANEMIA; ANGINA PECTORIS; ANORECTAL DISEASE; ANUS PRURITUS; ANXIETY DISORDER; AREA UNDER THE CURVE; CORONARY ARTERY DISEASE; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEMORRHOID; HEPATITIS; HEPATITIS C; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PRURITUS; REVIEW; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KETOCONAZOLE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84869994900     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2356     Document Type: Review

References (70)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16. (Pubitemid 30421405)
2. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74:2391-2399. (Pubitemid 23332300)
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46. (Pubitemid 35253462)
4. Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals. (Updated 25 April 2012. Accessed 3 October 2011.) Available from http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm
5. Mühlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9:34.
6. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50:899-909. (Pubitemid 43327793)
7. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6:3-16. (Pubitemid 43796632)
8. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002.
9. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA. INCIVEK (telaprevir). United States Prescribing Information 2012. (Updated June 2012. Accessed 11 July 2012.) Available from http://pi.vrtx.com/files/uspi-telaprevir. pdf
10. Janssen Pharmaceuticals, Beerse, Belgium. INCIVO (telaprevir). Summary of Product Characteristics 2011. (Accessed 11 July 2012.) Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/002313/WC500115529.pdf
11. Vertex Pharmaceuticals Incorporated, Laval, QC, Canada. INCIVEK (telaprevir). Canada Product Monograph 2011. (Updated 29 June 2012. Accessed 11 July 2012.) Available from http://pi.vrtx.com/files/canadapm-telaprevir-en.pdf
12. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011; 364:2405-2416.
13. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
15. van Heeswijk R, Boogaerts G, De Paepe E, et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir. 6th International Workshop on Clinical Pharmacology of HCV Therapy. 22-24 June 2011, Cambridge, MA, USA. Abstract PK-19.
16. Chakilam A, Chavan A, Smith G, et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin. 6th International Workshop on Clinical Pharmacology of HCV Therapy. 22-24 June 2011, Cambridge, MA, USA. Abstract PK-20.
17. Adiwijaya B, Chandorkar G, van Heeswijk R, et al. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics. 6th International Workshop on Clinical Pharmacology of HCV Therapy. 22-24 June 2011, Cambridge, MA, USA. Abstract PK-1.
18. Fraeyman NF, Dello CD, Belpaire FM. Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Br J Clin Pharmacol 1988; 25:733-740.
19. Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res Clin Exp 2001; 62:603-621. (Pubitemid 33016175)
20. Pegasys (peginterferon alfa-2a). Package insert 2011. Genentech, South San Francisco, CA, USA.
21. Rebetol (ribavirin USP). United States Prescribing Information 2010. Merck, Whitehouse Station, NJ, CA, USA.
22. Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009; 85:305-311.
23. van Heeswijk R, Van de Voorde A, Boogaerts G, et al. The effect of severe renal impairment on the pharmocokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol 2011; 54 Suppl 1:S492.
24. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-468.
25. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6:752-758.
26. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38:106-111. (Pubitemid 28117365)
27. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2012; doi: 10.1111/j.1365-2125.2012.04345.x.
28. Garg V, Luo X, McNair L, et al. The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-3 March 2011, Boston, MA, USA. Abstract 629.
29. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-1059.
30. Niemi M, Backmann JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819-850. (Pubitemid 36995083)
31. Garg V, Chandorkar G, Farmer H, Smith F, Alves K, van Heeswijk R. Effect of telaprevir on the pharamcokinetics of midazolam and digoxin. J Clin Pharmacol 2012; doi: 10.1177/0091270011419850.
32. Stoch SA, Friedman E, Maes A, et al. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 2009; 49:398-406.
33. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735-742.
34. Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 2009; 29:1175-1181.
35. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19:65-89. (Pubitemid 40173974)
36. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004; 10:45-76. (Pubitemid 38381174)
37. Luurila H, Kivisto KT, Nevonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998; 54:163-166. (Pubitemid 28204271)
38. Wennerholm A, Allqvist A, Svensson JO, et al. Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of a- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol 2005; 61:113-118. (Pubitemid 40674743)
39. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Pharmacokinetics and drug disposition. Clin Pharmacol Ther 2000; 67:335-341. (Pubitemid 30246808)
40. Luo X, van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmaokinetics of alprazolam and zolpidem in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HCV Therapy. 22-24 June 2011, Cambridge, MA, USA. Abstract PK-11.
41. Caduet (amlodipine besylate/atorvastatin calcium). Package insert 2006. Pfizer, New York, NY, USA.
42. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin Pharmacother 2004; 5:459-468. (Pubitemid 38219871)
43. McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol 1997; 48:336.
44. Nishio S, Watanabe H, Kosuge K, et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005; 28:223-227. (Pubitemid 40812606)
45. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28:125-130. (Pubitemid 30068994)
46. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006; 79:532-539. (Pubitemid 43833450)
47. Lee JE, van Heeswijk R, Alves K, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55:4569-4574.
48. Pham PA, la Porte CJL, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4385-4392.
49. Maltais F, Jung YC, Chen M, et al. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem 2009; 52:7993-8001.
50. van Heeswijk R, Boogaerts G, De Paepe E, et al. The pharmacokinetic (PK) interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir. Rev in Antiviral Ther and Inf Dis 2010; 5:12.
51. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46:281-290. (Pubitemid 46507007)
52. van Heeswijk R, Boogaerts G, De Paepe E, et al. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. 5th International Workshop on Clinical Pharmacology of HCV Therapy. 23-24 June 2010, Boston, MA, USA. Abstract 12.
53. Gutierrez M, Abramowitz W. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy 2001; 21:163-168. (Pubitemid 32119193)
54. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25:1200-1210. (Pubitemid 36532587)
55. Jage J. Methadone: pharmacokinetics and pharmacodynamics of an opiate. Anaesthesist 1989; 38:159-166.
56. Eap CB, Bourquin M, Martin J, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61:47-54.
57. Ferrari A, Coccia CP, Bertolini A, et al. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-559. (Pubitemid 39388966)
58. Kharasch ED, Bedynek PS, Park S, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008; 84:497-505.
59. van Heeswijk R, van de voorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir (TVR). J Hepatol 2011; 54 Suppl 1:S491-S492.
60. Benet LZ, Hoener BA. Changes in plasma proteins have little clinical relevance. Clin Pharmacol Ther 2002; 71:115-121. (Pubitemid 34271114)
61. Luo X, Trajevo J, van Heeswijk R, Garg V. No significant effect of the HCV protease inhibitor telaprevir on the pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers. HepDART 2011. 4-8 December 2011, Koloa, HI, USA. Abstract 132.
62. Li C, Liu T, Broske L, et al. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans. Biochem Pharmacol 2008; 76:1757-1764.
63. Schmitt C, Kaeser B, Riek M, et al. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther 2010; 48:192-199.
64. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76:73-84. (Pubitemid 38844736)
65. Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85:173-181.
66. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CAP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84:75-82. (Pubitemid 351861487)
67. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
68. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816-2820. (Pubitemid 350045781)
69. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC 08 study. Clin Pharmacokinet 2007; 46:941-952. (Pubitemid 47548643)
70. Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the investigational HCV protease inhibitor telaprevir. J Clin Pharmacol 2012; doi: 10.1177/0091270011419855.